Navigation Links
Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights
Date:7/30/2008

administrative 1,975 2,282 4,020 4,401

Total operating

expenses (2) 7,476 9,257 15,530 18,074

Interest income and

other, net 384 959 995 1,991

Net loss (2) $ (7,092) $ (6,996) $ (14,535) $(13,679)

Net loss per share, basic

and diluted (2) $ (0.25) $ (0.24) $ (0.51) $ (0.48)

Share used in calculating

net loss per share,

basic and diluted 28,731 28,638 28,714 28,629

(1) Includes $- and $317 as an offset in research and development

expense, which represents an estimate of the net reimbursement by

Novartis of ANA975 research and development costs for the three

months ended June 30, 2008 and 2007, respectively. Includes $43 and

$592 as an offset in research and development expense, which

represents an estimate of the net reimbursement by Novartis of ANA975

research and development costs for the six months ended June 30, 2008

and 2007, respectively.

(2) Includes non-cash operating expenses of $668 and $1,019 determined in

accordance with Statement of Financial Accounts Standards No. 123R,

"Share-Based Payment" (SFAS No. 123R) or approximately $0.02 and

$0.04 effect on basic and diluted net loss per common share for the

three months ended June 30, 2008 and 2007, respectively. Research and

development expense and general and administrative expense includes

$313 and $355 of non-cash operating expenses determined in accordance

with SFAS No. 123R for the three months ended June 30, 2008.

Includes non-cash operating expenses of $1,329 and $2,108 determined

in accordance with SFAS No. 123R or approximately $0.05 and $0.07

effect on basic and dilut
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Anadys Pharmaceuticals to Report Second Quarter 2008 Financial Results
2. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
3. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
4. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
5. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
6. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
7. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
8. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
9. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
10. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
11. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... Lenexa, KS (PRWEB) April 21, 2015 Contract ... has announced plans to relocate into a new 41,500 ft2 ... XenoTech’s global headquarters, currently located at 16825 W. 116th St. ... and a half times the customized laboratory space, will remain ... where the company was founded more than twenty years ago. ...
(Date:4/21/2015)... 21, 2015 AbilTo, Inc., the nation,s leading ... submission has been accepted as a presentation to be ... taking place on June 5-6, 2015 in Boston, ... American Diabetes Association, the cost of diabetes to the ... a result of increased inpatient, outpatient, and pharmacy costs, ...
(Date:4/21/2015)... Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today ... Thursday, April 23, 4:30 p.m. ET. Participants are invited ... Investor call information: U.S./ ... number: (925) 418-7845 Participant Passcode: 32888538 Questions ... , tina.amirkiai@fleishman.com . Access will be ...
(Date:4/21/2015)...  Tute Genomics, a leading provider of cloud-based genomic medicine ... as VP of Marketing. Mr. Forsythe is the latest to ... its commercial operations over the last two quarters. ... is a tremendous addition to the Tute Genomics team," ... Genomics. "Josh,s vast experience commercializing software technology in a highly ...
Breaking Biology Technology:XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014 2XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014 3AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 2AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 3Ampio Announces Investor Call on Thursday, April 23, 4:30 p.m. ET 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 4
... AMLN ) will be presenting at the FBR ... 28, 2008 at 9:45 a.m. ET / 6:45,a.m. PT. ... Pharmaceuticals, will be providing a corporate overview., The ... a,recording will be made available following the event. The ...
... AstraZeneca (NYSE:,AZN) announced today that it supports ... the company,s latest step to provide the public,with ... Sponsored by Sens. Charles Grassley of Iowa ... a national registry of payments that,biopharmaceutical companies, device ...
... Biosciences,Corporation (Nasdaq: MATK ) announced that it intends ... 2008 on June 4, 2008, at approximately 4:00,p.m. Eastern ... Martek will,conduct a conference call to discuss the results ... interested parties may listen to the call,live via webcast ...
Cached Biology Technology:AstraZeneca Supports Transparency Legislation on Payments to Health Care Providers 2
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/13/2015)... 2015 According to a ... Market Forecast & Opportunities, 2020", the global biometrics market ... 14% till 2020. The biometrics market is garnering ... and review of biometric management systems. The constant ... with greater efficiency, are resulting in increasing installation ...
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... Scientists have been working for more than a ... genes within cells. Now researchers have discovered that microRNA ... each other and ultimately determine the types of cells ... implications in a wide range of fields, including medical ...
... ARBOR, Mich.---As a way to simplify lab-on-a-chip devices ... medical tests, University of Michigan researchers have created ... intelligently route the flow of electricity on computer ... the flow of fluid through their devices without ...
... available in <A HREF=",http://chinese.eurekalert.org/zh/pub_releases/2010-04/sfeb-phr042210.php,">Chinese . A ... extraordinarily complex fluctuations across a wide range of time ... clinical and dynamical significance it may provide warning ... the heart,s pacemaking system. In work published in ...
Cached Biology News:Production of biofuels could benefit by controlling the types of cells that develop in plants 2Microfluidic integrated circuit could help enable home diagnostic tests 2Microfluidic integrated circuit could help enable home diagnostic tests 3Periodic heart rate decelerations in premature infants 2Periodic heart rate decelerations in premature infants 3
Mouse monoclonal antibody to QPCT - glutaminyl-peptide cyclotransferase (glutaminyl cyclase)...
... MSY2/YBOX2 ( Abpromise for all ... Synthetic peptide derived from a ... human YBX2. (Note: the exact ... Entrez Gene ...
Rabbit polyclonal to YANK2 ( Abpromise for all tested applications). Antigen: A KLH conjugated synthetic peptide selected within aa 300~400 (C terminal region) of human YANK2. Entrez Gene ID:...
Certified by the Biological Stain Commission. For staining fresh peripheral blood smears and blood parasites....
Biology Products: